Mondelez Q2 Volume Turns Positive but Margins Lag, Recovery Still Incomplete

What happened

Mondelez reported Q2 2026 organic net revenue growth of 2.2% and a return to positive volume/mix, with North America regaining momentum, a notable reversal from the sustained volume declines that pressured shares through 2025. This top-line improvement addresses one of the key concerns from the prior DeepValue analysis, which highlighted negative global volume/mix and weak U.S. biscuit volumes as risks to the earnings recovery thesis. However, profitability remained constrained, as underlying gross margin expansion was only modest once significant mark-to-market derivative gains were excluded, signaling that cocoa cost deflation and other input tailwinds have not yet translated into meaningful margin repair. The earnings recovery story thus remains incomplete: while volume stabilization is a necessary condition, the market still requires evidence of sustainable margin expansion to justify the high-single-digit EPS growth assumed by the valuation at the time of the master report. Overall, the Q2 print offers encouraging but insufficient proof that the broader cost and elasticity headwinds identified earlier are fully dissipating.

Implication

Investors should treat the positive volume/mix and North American momentum as a step in the right direction but not yet a signal to buy, given that gross margin expansion remains modest and the prior thesis of high-single-digit EPS growth is still unproven. The article suggests that underlying profitability has not meaningfully improved, so the stock may continue to trade in a range until Q3 results provide clearer evidence of margin inflection driven by cocoa deflation and cost controls. For current holders, the position can be maintained, but new capital should wait for either a pullback toward more attractive levels or a confirmed gross margin recovery above 35% as outlined in the DeepValue report. Conversely, if forthcoming quarters show volume/mix consistently positive and margins expanding strongly, the thesis would shift toward a more bullish stance. Until then, the balance of risk and reward remains neutral, favoring patience over action.

Thesis delta

The original thesis argued that MDLZ faced broader cost and volume headwinds than a simple cocoa shock, warranting a wait for lower entry or clearer proof of repair. Q2 2026 volume/mix turning positive and North America regaining momentum partially addresses the volume concern, raising confidence that the base-case recovery is on track. However, the modest underlying gross margin expansion suggests that input cost relief is not yet flowing through strongly, so the core conclusion—that high-single-digit EPS growth is not assured—remains intact, and the rating stays WAIT.